Cargando…

Poly(vinylidene fluoride) Intestinal Sleeve Implants for the Treatment of Obesity and Type 2 Diabetes

Currently, treatment of diabetes and associated obesity involves Roux-en-Y gastric bypass or sleeve gastrectomy to reduce the absorption of nutrients from the intestine to achieve blood glucose control. However, the surgical procedure and subsequent recovery are physically and psychologically burden...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Hao-Ming, Zhan, Wei-Ping, Tsai, Hsieh-Chih, Yang, Meng-Ru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183030/
https://www.ncbi.nlm.nih.gov/pubmed/35683855
http://dx.doi.org/10.3390/polym14112178
_version_ 1784724188046557184
author Chang, Hao-Ming
Zhan, Wei-Ping
Tsai, Hsieh-Chih
Yang, Meng-Ru
author_facet Chang, Hao-Ming
Zhan, Wei-Ping
Tsai, Hsieh-Chih
Yang, Meng-Ru
author_sort Chang, Hao-Ming
collection PubMed
description Currently, treatment of diabetes and associated obesity involves Roux-en-Y gastric bypass or sleeve gastrectomy to reduce the absorption of nutrients from the intestine to achieve blood glucose control. However, the surgical procedure and subsequent recovery are physically and psychologically burdensome for patients, with possible side effects, so alternative treatments are being developed. In this study, two methods, solution casting and machine direction orientation (MDO), were used to prepare intestinal implants made of poly(vinylidene fluoride) (PVDF) film and implant them into the duodenum of type 2 diabetic rats for the treatment of obesity and blood glucose control. The PVDF film obtained by the MDO process was characterized by FT-IR, Raman spectroscopy, XRD and piezoelectricity tests, which showed higher composition of β crystalline phase and better elongation and mechanical strength in specific directions. Therefore, the material was finally tested on rats after it was proven to be non-toxic by biological toxicity tests. The PVDF was implanted into alloxan-induced diabetic rats, which were used as a model of impaired insulin secretion due to pancreatic beta cell destruction rather than obesity-induced diabetes, and rats were tracked for 24 days, showing significantly improved body weight and blood glucose levels. As an alternative therapeutic option, intestinal sleeve implant showed future potential for application.
format Online
Article
Text
id pubmed-9183030
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91830302022-06-10 Poly(vinylidene fluoride) Intestinal Sleeve Implants for the Treatment of Obesity and Type 2 Diabetes Chang, Hao-Ming Zhan, Wei-Ping Tsai, Hsieh-Chih Yang, Meng-Ru Polymers (Basel) Article Currently, treatment of diabetes and associated obesity involves Roux-en-Y gastric bypass or sleeve gastrectomy to reduce the absorption of nutrients from the intestine to achieve blood glucose control. However, the surgical procedure and subsequent recovery are physically and psychologically burdensome for patients, with possible side effects, so alternative treatments are being developed. In this study, two methods, solution casting and machine direction orientation (MDO), were used to prepare intestinal implants made of poly(vinylidene fluoride) (PVDF) film and implant them into the duodenum of type 2 diabetic rats for the treatment of obesity and blood glucose control. The PVDF film obtained by the MDO process was characterized by FT-IR, Raman spectroscopy, XRD and piezoelectricity tests, which showed higher composition of β crystalline phase and better elongation and mechanical strength in specific directions. Therefore, the material was finally tested on rats after it was proven to be non-toxic by biological toxicity tests. The PVDF was implanted into alloxan-induced diabetic rats, which were used as a model of impaired insulin secretion due to pancreatic beta cell destruction rather than obesity-induced diabetes, and rats were tracked for 24 days, showing significantly improved body weight and blood glucose levels. As an alternative therapeutic option, intestinal sleeve implant showed future potential for application. MDPI 2022-05-27 /pmc/articles/PMC9183030/ /pubmed/35683855 http://dx.doi.org/10.3390/polym14112178 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chang, Hao-Ming
Zhan, Wei-Ping
Tsai, Hsieh-Chih
Yang, Meng-Ru
Poly(vinylidene fluoride) Intestinal Sleeve Implants for the Treatment of Obesity and Type 2 Diabetes
title Poly(vinylidene fluoride) Intestinal Sleeve Implants for the Treatment of Obesity and Type 2 Diabetes
title_full Poly(vinylidene fluoride) Intestinal Sleeve Implants for the Treatment of Obesity and Type 2 Diabetes
title_fullStr Poly(vinylidene fluoride) Intestinal Sleeve Implants for the Treatment of Obesity and Type 2 Diabetes
title_full_unstemmed Poly(vinylidene fluoride) Intestinal Sleeve Implants for the Treatment of Obesity and Type 2 Diabetes
title_short Poly(vinylidene fluoride) Intestinal Sleeve Implants for the Treatment of Obesity and Type 2 Diabetes
title_sort poly(vinylidene fluoride) intestinal sleeve implants for the treatment of obesity and type 2 diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183030/
https://www.ncbi.nlm.nih.gov/pubmed/35683855
http://dx.doi.org/10.3390/polym14112178
work_keys_str_mv AT changhaoming polyvinylidenefluorideintestinalsleeveimplantsforthetreatmentofobesityandtype2diabetes
AT zhanweiping polyvinylidenefluorideintestinalsleeveimplantsforthetreatmentofobesityandtype2diabetes
AT tsaihsiehchih polyvinylidenefluorideintestinalsleeveimplantsforthetreatmentofobesityandtype2diabetes
AT yangmengru polyvinylidenefluorideintestinalsleeveimplantsforthetreatmentofobesityandtype2diabetes